BRISBANE: Fiji Kava Ltd, an Australian-Fijian medicinal kava health and wellness company, announced a non-exclusive licence agreement with BioCeuticals, a Blackmores-owned company, to develop a co-branded product for release in Australia and New Zealand.

The agreement will see BioCeuticals licence the use of Fiji Kava’s high quality noble kava extract for its BioCeuticals Clinical AnxioCalm product, which is a unique blend of herbs to support symptomatic relief of mild anxiety, tension and stress, formulated to calm and support the nervous system and to minimise stress.

The AnxioCalm products will be co-branded with Fiji Kava’s ‘Authentic Fiji Kava’ trademark clearly and prominently displayed on each product sold. The AnxioCalm products will be available through BioCeuticals extensive networkof qualified healthcare practitioners across Australia and New Zealand.

Founder and CEO, Mr Zane Yoshida, said: “This is another milestone for the company that will not only increase the availability of our noble kava in Australia and New Zealand, but is another strong endorsement by a leading healthcare provider of the quality and uniqueness of our Fijian noble kava.

“In particular, we are proud to support BioCeuticals with our water extracted Noble Fiji Kava, as allowed by the TGA in Australia. We are able to deliver this to BioCeuticals and our other partners through our vertically integrated supply chain, guaranteeing a sustainable and 100% traceable supply of unadulterated Noble Fiji Kava.

“Fiji Kava will continue to scale-up its production in Fiji to produce required inventory to meet the growing demand from the BioCeuticals licence agreement and other recent business development advancements such as ranging in Coles Supermarkets nationally”.

The agreement with BioCeuticals continues a period of strong and sustained progress being made by the company on its commercial strategy to grow the availability of its Fijian noble kava. The company now has cornerstone retail agreements in place in targeted markets, such as Coles Supermarkets in Australia and Green Cross Pharmacy in New Zealand; and has expanded its e-commerce presence on Amazon in the United States, while exploring opportunities to access Chinese marketplaces.

Fiji Kava will supply BioCeuticals with its noble kava via its agreement with Pathway International.

Fiji Kava Ltd (ASX: FIJ), an Australian-Fijian medicinal kava health & wellness company, producing natural ‘noble kava’ products for the complementary and alternative medicine market, estimated to exceed USD $210 billion by 2026 globally. As the first foreign company with approval from the Fijian Government to operate in the kava industry. Fiji Kava has established a global leading sustainable and 100% traceable supply chain of ‘noble kava’ via its world first kava tissue culture laboratory and 111-acre nucleus farm in Levuka, on the island of Ovalau, Fiji.

Fiji Kava signs MoU to explore Chinese ecommerce and Diagou marketplace opportunities